The company (Stock Code: 002821.SZ/6821.HK) is a leading global CDMO company providing high-quality one-stop service for R & D and production of new drugs around the world. In order to speed up the marketing of new drugs and prolong the quality of life, relying on continuous technological innovation, we can provide pharmaceutical companies and biotechnology companies with one-stop CMC services in the whole life cycle of drugs, and speed up the development and application of new drugs. The company is a global leading, technology-driven CDMO one-stop integrated service provider. Speed up the clinical research and commercial application of innovative drugs by providing domestic and foreign pharmaceutical and biotechnology companies with one-stop CMC services throughout the drug life cycle, efficient and high-quality R & D and production services. By providing domestic and foreign pharmaceutical companies and biotechnology companies with one-stop CMC services throughout the drug life cycle, efficient and high-quality R & D and production services in 2019, the company was awarded the "Best partner for the Transformation and upgrading of Chinese Pharmaceutical Enterprises in 2019". A total of 6 award-winning enterprises / institutions were selected. As the only pharmaceutical CDMO company on the list, the company has excellent quality and service, good reputation and reputation. After many layers of screening to win the award-this is also the company to win this honor again. It won two awards of "Top 100 of China Pharmaceutical Industry" and "Top 20 Chinese Pharmaceutical Outsourcing companies" in the 2018 list of the most influential Chinese Pharmaceutical Industry released by the all-China Federation of Industry and Commerce. It fully demonstrates the strong competitiveness and strong growth of the company as a benchmark in the industry.